The off-label use of medicines is a common and extensive clinical practice. Omalizumab has
been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing …

Omalizumab is a monoclonal anti-IgE antibody that has been used to treat allergic asthma
for over a decade. The use of omalizumab to treat other diseases has largely been limited to …

INTRODUCTION: Omalizumab has been demonstrated to be a successful therapy in the
management of asthma through reduction of patient's symptoms and use of inhaled …

Omalizumab is a biological engineered molecule, targeting the Cε3 domain of the IgE
molecule. It binds with free IgE and prevents free IgE from attaching to high-affinity IgE …

Introduction: The evolution in immunological methods used to assess human allergic
diseases has led to the identification of immunoglobulin E (IgE) as a diagnostic biomarker …

From its availability for clinical use nearly two decades ago for severe asthma, omalizumab
has gained strong evidence of efficacy and safety in the treatment of severe asthma not …

Omalizumab is a humanized, monoclonal anti-IgE antibody that binds specifically to
circulating IgE molecules, thus interrupting the allergic cascade. Omalizumab has been …

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐
IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent …

Omalizumab, a monoclonal antibody that targets circulating IgE, is approved as add-on
therapy for adult and adolescent patients with severe allergic asthma in the EU and …

Omalizumab, a recombinant humanized monoclonal antibody against immunoglobulin (Ig)
E, represents a unique therapeutic approach for the treatment of allergic diseases. This …